But the only unifying hypothesis I can think of that can account for all those abnormalities, without requiring new understandings of human biology, is one of pathogenic causation or co-causation. And as acer2000 pointed out, those things by themselves represent a diffuse constellation of potential markers with only limited insight into pathophysiology.
The CAA has been fishing for biomarkers too exclusively for too long; there are many problems with this approach, including the poor definition of the disease itself (even Fukuda would include overlapping, unrelated conditions) and therefore of 'true' patient cohorts, but also the basic problem that the search parameters are too wide... Looking for biomarkers is like looking for a needle in a colossal haystack (i.e. the sum of possible biological parameters interacting with the sum of biological and environmental variables). It would make far more sense for an organization with a very limited research budget like the CAA to formulate, based on available biomedical research, a set of co-existing hypotheses for the pathophysiology of ME/CFS and to look for evidence of the causal mechanisms posited by those hypotheses. This is exactly what the WPI did. Instead, the CAA - and many other researchers - have tended to investigate rather peripheral associations between disease and certain biological parameters that do not encompass a central hypothesis of disease causation and that in themselves would, at best, only suggest a possible correlating pathophysiology. As I said this has been the sort of piecemeal approach prevalent in the research community as a whole towards CFS, but the CAA was in the position to do what the WPI ultimately did: to focus on investigating a particular hypothesis of what is going on in ME/CFS, particularly one involving viral pathogenesis, for which the biomedical evidence (despite what Dr. Vernon asserts in the linked article) has always been the strongest.
The CAA research strategy has been to cast a wide net and look for anything that correlates to (rather vaguely defined) illness in CFS patients, but with necessarily limited funding this has never seemed to me like an efficient approach. And even in the search for biomarkers they seem to have ignored two of the most compelling findings in ME/CFS research: abnormal SPECT, PET, and fMRI scans, and low circulating blood volume. To complement the work being done by the WPI and others, I would love to see the CAA expand efforts to look for these abnormalities in CCC-defined cohorts. The studies with Drs. Medow and Shungu hint in this direction, but are again essentially looking for different markers.
My apologies for spamming!